Stock ARLZQ OLD API WIND-DOWN LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Old API Wind-down Ltd.

Equities

ARLZQ

CA03852X1006

Delayed OTC Markets
Other stock markets
 		5-day change 1st Jan Change
- USD -.--% Intraday chart for Old API Wind-down Ltd. -.--% -.--%
2019 Old API Wind-Down Ltd. Announces Management Changes CI
2019 Aralez Pharmaceuticals Inc. has Changed its Name to Old API Wind-down Ltd CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Old API Wind-Down Ltd. Announces Management Changes
CI
Aralez Pharmaceuticals Inc. has Changed its Name to Old API Wind-down Ltd
CI
Aralez Pharmaceuticals Inc. Announces Management Changes
CI
Nuvo Pharmaceuticals Inc. completed the acquisition of Aralez Pharmaceuticals Canada Inc. from Aralez Pharmaceuticals Inc..
CI
Aralez Pharmaceuticals Inc.(NasdaqGS:ARLZ) dropped from NASDAQ Composite Index
CI
Aralez Pharmaceuticals Inc. Announces the Resignation of Seth A. Rudnick, Neal F. Fowler and Rob Harris as Directors
CI
Nuvo Pharmaceuticals Inc. signed a letter of intent to acquire Aralez Pharmaceuticals Canada Inc. from Aralez Pharmaceuticals Inc. for $62.5 million.
CI
Aralez Pharmaceuticals Inc. Announces Resignation of James Tursi as Chief Medical Officer, Effective from August 2, 2018
CI
Aralez Pharmaceuticals Inc. Enters into an Amendment to that Certain Second Amended and Restated Facility Agreement with Deerfield Partners, L.P
CI
Transcript : Aralez Pharmaceuticals Inc., Q1 2018 Earnings Call, May 08, 2018
Aralez Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2018
CI
Aralez Pharmaceuticals Inc. Announces Resignation of Mark Glickman as Chief Commercial Officer, Effective on March 30, 2018
CI
Aralez Pharmaceuticals Inc. Appoints Michael Kaseta as Chief Financial Officer
CI
Transcript : Aralez Pharmaceuticals Inc., Q4 2017 Earnings Call, Mar 13, 2018
Aralez Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2017; Provides Earnings Guidance for the Fiscal Year 2018
CI
Aralez Pharmaceuticals Inc.(NasdaqGS:ARLZ) dropped from NASDAQ Biotechnology Index
CI
Aralez Pharmaceuticals Inc. Announces Executive Changes
CI
Transcript : Aralez Pharmaceuticals Inc., Q3 2017 Earnings Call, Nov 09, 2017
Aralez Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017; Revises Earnings Guidance for the Year Ending December 31, 2017 and provides Preliminary Guidance for Full Year Ending December 31, 2018
CI
Aralez Pharmaceuticals Inc.(NasdaqGS:ARLZ) dropped from S&P Global BMI Index
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ARLZQ Stock
  4. News Old API Wind-down Ltd.